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ABSTRACT
Hyperandrogenism, obesity, and hyperinsulinemia may protect against osteoporosis, whereas amenorrhea, increased cortisol, and
low growth hormone may be associated with higher fracture risk in polycystic ovary syndrome (PCOS). The objective of this study
was to investigate fracture risk in PCOS. In the PCOS Denmark study, women with PCOS and/or hirsutism were identiﬁed in the
Danish National Patient Register (1995–2012). Each patient was assigned three age-matched controls on the index date of PCOS
diagnosis. Individuals with a previous endocrine diagnosis were excluded. Within PCOS Denmark, we embedded a well-
characterized subcohort of patients, PCOS OUH, diagnosed with PCOS at Odense University Hospital (n¼ 1217). We identiﬁed
incident fractures by International Classiﬁcation of Diseases, 10th Revision (ICD-10) codes and used conditional Cox regression
analyses to compare fracture risk. In the PCOS Denmark study, there were 19,199 women with PCOS and 57,483 controls were
included, mean age 30.6 years (range, 12–60 years). Fracture rates were decreased in PCOS Denmark (10.3/1000 patient years) versus
controls (13.6/1000 patient years). The adjusted ORs were 0.76 (95% CI, 0.71 to 0.80) for all fractures, 0.82 (95% CI, 0.74 to 0.92) for
major osteoporotic fractures, and 0.57 (95% CI, 0.47 to 0.70) for fractures of head and face. The risk reduction was more pronounced
below the age of 30 years at diagnosis. Women with PCOS had signiﬁcant more hospital contacts due to strains and sprains. In the
PCOS OUH subcohort, the risk reduction of fractures did not differ between PCOS women with elevated versus normal testosterone
levels and the risk reduction was nominally smaller in overweight versus normal weight PCOS women. Women with PCOS had
reduced risk of fractures, in particular of the appendicular skeleton. The risk reduction was greater in women with younger age at
diagnosis suggesting that the skeletal effects of PCOSmay be greater in womenwho have not yet reached peak bonemass. Reduced
participation in sports activities was probably not the reason for the reduced risk of fractures. © 2015 The Authors. Journal of Bone
and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR).
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Introduction
Osteoporosis is a major global health concern and osteopo-rotic fracture is particularly prevalent among postmeno-
pausal women. Much research has naturally been conducted
regarding determinants of accelerated bone loss rates, either
after menopause or after the onset of major illnesses or
introduction of drugs with adverse bone outcomes such as
glucocorticoids, aromatase inhibitors, and glitazones.(1) How-
ever, a simple mathematical appraisal of the impact of peak
bone mass demonstrates that a modest 1 SD higher peak bone
mass is sufﬁcient to offset almost three decades of bone loss at
1 SD above the normal rate.(2) The importance of bone health
in uteri, in childhood, adolescence, and young adulthood on
the subsequent risks of osteoporosis is slowly becoming
recognized.(3)
Polycystic ovary syndrome (PCOS) affects 6% to 20% of
women of reproductive age and the syndrome is therefore the
most frequent endocrinopathy in premenopausal women.(4)
PCOS is most often deﬁned according to the Rotterdam criteria,
which include two out of the following three: (1) irregular/no
ovulations; (2) clinical/biochemical hyperandrogenemia; and
(3) polycystic ovaries.(5) Secondary etiologies such as hyper-
prolactinemia, acromegaly, Cushing’s syndrome, adrenogenital
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Received in original form September 28, 2015; revised form October 26, 2015; accepted November 4, 2015. Accepted manuscript online December 6, 2015.
Address correspondence to: Bo Abrahamsen, MD, PhD, Consultant Endocrinologist, Department of Medicine, Holbæk Hospital, DK-4300 Holbæk, Denmark.
E-mail: b.abrahamsen@physician.dk
ORIGINAL ARTICLE JBMR
Journal of Bone and Mineral Research, Vol. 31, No. 4, April 2016, pp 709–717
DOI: 10.1002/jbmr.2737
© 2015 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR).
709
syndrome, and Turner’s syndrome should be excluded.(5)
The prevalence of hirsutism is 5% to 25% in women of
reproductive age(6) and PCOS is diagnosed in more than 90% of
these patients.(6) PCOS has so far not been extensively studied in
terms of skeletal outcomes, though the associated hyper-
androgenemia, obesity, and insulin resistance may protect
patients’ bone health, whereas amenorrhea, increased risk of
type 2 diabetes, hypovitaminosis D, low growth hormone levels,
and increased cortisol may be associated with lower bone
mineral density (BMD).(7,8)
Studies regarding BMD in premenopausal study populations
found comparable or higher BMD in patients with PCOS and/or
hirsutism compared to controls.(8) The majority of these studies
were, however, performed in very small study populations
(<50 patients) with hirsutism and/or PCOS and uniform criteria
were not applied for the diagnosis of PCOS.(8) One Swedish
study found no difference in fracture risk over more than
20 years in womenwith PCOS and elevated androgen levels, but
the study only included 25 patients and 68 control subjects.(9)
We are not aware of other studies on fracture risk in patients
with PCOS.
The aim of this study was to investigate fracture risk in
patients diagnosed with PCOS/hirsutism. We hypothesized that
fracture risk could be lower in patients with PCOS than in healthy
controls due to higher androgen levels, hyperinsulinemia, and
obesity, which could lead to increased BMD.
Materials and Methods
Study population and data sources
We have conducted an open, observational, register-based
cohort study using national health data. Study design and
baseline data of the cohort have been reported previously.(10)
Inbrief,weusedDanishNational Registers to identify allwomen
in the country who were diagnosed through a hospital contact
(inpatient or outpatient) as having PCOS (E282) and/or hirsutism
(L680) between January 1, 1995, and the end of 2012 (PCOS
Denmark). We excluded patients who were below age 12 years or
over age 60 years, and patients with a history of endocrine
disorders that could give rise to signs or symptoms similar to
PCOS, namely E221 (hyperprolactinemia), E220 (acromegaly), E24
(Cushing’s syndrome), E25 (adrenogenital syndrome), and Q96
(Turner syndrome). For each patient with PCOS/hirsutism, three
control women born in the same year as the patient were
randomly drawn from the civil population register. Controls were
assigned the index date (date of ﬁrst PCOS diagnosis) of their
matched PCOS cases. Controls had tobe alive on the index date of
their respective PCOS case. We retrieved information about
hospital contacts and prescriptions ﬁlled, along with dates of
death if applicable, in both PCOS patients and control subjects
fromDanishNational Registers, theNational Prescription Registry,
and the National Cause of Death Register. The Registers are in
relation to this study population described elsewhere.(10)
Within the national PCOS cohort, we embedded a local
subcohort of all patients with PCOS treated at Odense University
Hospital (OUH) (n¼ 1,217). As described,(10) this subcohort
(PCOS OUH) is very similar to patients in PCOS Denmark though
the mean age and the number of childbirths were marginally
lower in the local cohort. Although the PCOS Denmark cohort
contained information about hospital diagnoses and ﬁlled
prescriptions only, the PCOS OUH subcohort also had detailed
information on androgen levels, body mass index, and other
key biochemical and clinical characteristics as described by
Glintborg and colleagues.(11)
The study was not a clinical trial. Ethics committee approval
was therefore not required. Data was accessed through Statistics
Denmark, project number 704175, and was approved by the
Data Protection Agency.
Outcome
The primary outcome was any fracture, whereas secondary
outcomes were (1) major osteoporotic fractures (fractures
assumed to be BMD-dependent), ie, fractures of the forearm,
spine, hip, or humerus(12) and (2) fractures not likely to be
BMD-dependent, ie, fractures of the hands, head, and face.(13)
We identiﬁed incident fractures by International Classiﬁcation of
Diseases, 10th Revision (ICD-10) codes (Table 1) from the Danish
National Registers.
Statistical analyses
Baseline characteristics are shown as mean SD or median
(range) as appropriate. Chi square test and Mann-Whitney
U tests were used to test for difference between PCOS and
control group for categorical and continuous variables,
respectively. Values of p <0.05 were considered statistically
signiﬁcant.
Cox proportional hazard models were used to calculate
incidence rates, hazard ratios, and 95% conﬁdence intervals
(95% CIs) for fracture outcomes using the ICD-10 codes for
fractures shown in Table 1.
Sensitivity analyses were performed by reanalyzing data
stratiﬁed by age (<30 years and30 years), omitting thewomen
below the age of 50 years and in analyses only including women
and their respective controls from the PCOS OUH cohort.
The SAS Greedy Match macro (SAS Institute, Inc., Cary, NC,
USA) was used in the matching procedure and STATA version 13
(Stata Corporation, Inc., College Station, TX, USA) was used for
the analyses.
Results
The National cohort included 76,682 women and was
composed of 19,199 patients making up PCOS Denmark and
57,483 control subjects (Fig. 1). The cohort contained an
embedded local cohort of 1217 patients (PCOS OUH) from
Odense University Hospital as described in the Materials and
Methods section.
Key baseline characteristics of the participants are shown in
Table 1 (additional clinical characteristics are described in the
article by Glintborg and colleagues(10)).
In PCOS Denmark, the mean age was 30.6 years (range, 12–60
years) at diagnosis. Patients with PCOS were less likely to have a
prior history of fractures (12.0% versus 16.1%, p< 0.001). This
was also true for sites not conventionally considered linked to
BMD; eg, fractures of head and face, hands, or feet. Patients in
PCOS Denmark had signiﬁcant more hospital contacts com-
pared to controls due to strains and sprains both with regard to
typically sports-related strains and sprains and also with regard
to strains and sprains in general (21.8% versus 20.9%, p¼ 0.01,
and 24.6% versus 23.7%, p¼ 0.01, respectively). They also had a
higher prevalence of most baseline conditions compared to
controls, in particular diseases related to the cardiovascular
system—with a three times higher prevalence of dyslipidemia
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and hypertension—and endocrine disorders, with an increased
prevalence of diabetes, obesity, and thyroid disorders (Table 1).
PCOS patients more often had a history of prednisolone,
metformin, oral contraceptives, and cyproterone acetate/ethinyl
estradiol exposure than controls (Table 1).
Fracture incidence
A total of 1596 (8.3%) in PCOS Denmark and 6148 (10.7%)
controls suffered at least one fracture, corresponding to an
incidence rate of 10.3 versus 13.6 per 1000 patient-years
(Table 2). Most fractures occurred at sites not regarded as major
osteoporotic, or classically BMD-dependent, fracture sites. The
rate of major osteoporotic fractures was 2.6 per 1000 patient-
years in PCOS Denmark and 3.0 per 1000 patient-years in control
subjects, whereas fractures of the hands occurred at a rate of 3.0
(PCOS Denmark) versus 4.5 (control) per 1000 patient-years. The
overall fracture risk was signiﬁcantly reduced in patients with
PCOS (HR 0.76; 95% CI, 0.72 to 0.80; p< 0.001) and adjustment
for Charlson index, comorbid conditions (obesity, diabetes,
dyslipidemia, hyperthyroidism, and hypothyroidism), prior
fractures, and prior prednisolone use did not change results
(Table 2, Fig. 2). The risk reduction was more pronounced in
fractures of the hands (adjusted HR 0.68; 95% CI, 0.62 to
0.76; p< 0.001), head and face (adjusted HR 0.57; 95% CI, 0.47 to
0.70; p< 0.001) than at major osteoporotic sites (adjusted HR
0.82; 95% CI, 0.74 to 0.92; p¼ 0.001) (Table 2). There was no
interaction with baseline fracture prevalence, but a signiﬁcant
interaction with age was observed for fractures in general
(p< 0.001) and for fractures of the hands (p< 0.001) or head and
face (p¼ 0.04). Sensitivity analyses, wherewomen above the age
of 50 years at the ﬁrst diagnosis of PCOS were excluded, did not
signiﬁcantly change ﬁndings at any of the fracture sites (data
not shown). Stratifying the analyses for age (Table 3) by dividing
the population into those aged<30 years or30 years, revealed
a more pronounced relative risk reduction in patients<30 years
at the time of diagnosis. Though fractures of the hip and
femur nominally exhibited a smaller risk reduction in the older
age group, this difference was not statistically signiﬁcant
(pinteract 0.63).
Table 1. Baseline Characteristics of Patients and Controls
PCOS Controls
n¼ 19,199 n¼ 57,483 p
Age (years), mean SD 30.6 9.6 30.6 9.6 0.96
Age (years), range 12 to 60 12 to 60
Charlson index, mean SD 0.155 0.537 0.096 0.435 <0.001
ICD-10 codes n % n % P
Fracture history
All prior fractures 2,481 12.92 9,280 16.14 <0.001
Head or face S02 251 1.31 1,349 2.35 <0.001
cervical spine S12 8 0.04 57 0.10 0.015
Sternum S222 3 0.02 10 0.02 1.000
Ribs S223-S225 16 0.08 119 0.21 <0.001
Pelvis S321-S329 43 0.22 88 0.15 0.043
Spine S220, S221, S320 29 0.15 125 0.22 0.077
Clavicle and scapula S420, S421 81 0.42 540 0.94 <0.001
Humerus S422-S499 118 0.61 435 0.76 0.043
Forearm S52 676 3.52 2,267 3.94 0.008
Hand S62 909 4.73 3,548 6.17 <0.001
Hip and femur S720-S729 22 0.11 140 0.24 0.001
Lower leg S82 375 1.95 1,302 2.27 0.010
Foot S92 462 2.41 1,519 2.64 0.074
Major osteoporotic fracturesa 796 4.15 2,757 4.80 <0.001
All strains and sprains 4,721 24.59 13,605 23.67 0.010
Sports related strains and sprains S63, S83, S93 4,185 21.80 12,024 20.92 0.010
Medical history
Obesity E66 2,306 12.01 791 1.38 <0.001
Diabetes E10, E11, E13, E14 429 2.23 423 0.74 <0.001
Dyslipidaemia E78 107 0.56 108 0.19 <0.001
Hypertension I109 343 1.79 365 0.63 <0.001
Cardiovascular disease I20, I50 72 0.38 177 0.31 0.16
Myocardial infarction I21, I22, I23, I24, I25 39 0.20 121 0.20 0.85
Thyroid disease E04, E05, E03 476 2.48 379 0.66 <0.001
Hyperthyroidism E05 150 0.78 159 0.28 <0.001
Hypothyroidism E03 213 1.11 106 0.18 <0.001
Medication history (last year) ATC codes n % n % P
Prednisolone H02AB06, H02AB07 882 4.59 1,687 2.93 <0.001
Metformin A10BA02 1,795 9.35 146 0.25 <0.001
Oral contraceptives G03AA, G03AB 3,716 19.36 10,031 17.45 <0.001
Cyproterone acetate/ ethinylestradiol G03HB01 1,347 7.02 533 0.93 <0.001
PCOS ¼ polycystic ovary syndrome; ICD-10 ¼ International Classiﬁcation of Diseases, 10th Revision; ATC ¼ Anatomical Therapeutic Chemical.
aSpine, humerus, and forearm.
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Contributing factors as assessed in the embedded
clinical PCOS OUH cohort
Addressing the inﬂuence of obesity and androgen levels for
fracture risk was possible in PCOS OUH (n¼ 1217) (Table 4). As
reported,(10) these women had a mean age of 29.3 (median 29;
interquartile range [IQR], 23 to 35) years, BMI median 27.3 (IQR,
23.0 to 32.7) kg/m2, total testosterone 1.74 (IQR, 1.24 to 2.38)
nmol/L, free testosterone 0.033 (IQR, 0.021 to 0.050) nmol/L
(data not shown). Repeating the analyses of overall fracture risk
in the PCOS OUH cohort conﬁrmed a similarly decreased risk of
fractures as observed in the full PCOS Denmark cohort (adjusted
HR 0.66; 95% CI, 0.51 to 0.84; p¼ 0.001). Data on BMI was
available in 1130 women in the PCOS OUH cohort, and
subdividing this cohort into patients with BMI <25 kg/m2
(n¼ 431) and BMI 25 kg/m2 (n¼ 699) revealed that the risk
reduction relative to population controls was nominally more
pronounced in patients with BMI <25 kg/m2 (HR, 0.52; 95% CI,
0.34 to 0.78; p¼ 0.002) than in overweight patients (HR, 0.74;
95% CI, 0.53 to 1.03; p¼ 0.08). A formal interaction test should
not be undertaken because it is not possible to subdivide
population controls by BMI status but overlapping conﬁdence
intervals should be noted. A total of 64 patients in PCOS OUH
had BMI <20 kg/m2. Omitting these patients in a sensitivity
analyses did not signiﬁcantly change the results. PCOS OUH
patients with elevated free or total testosterone levels had a
signiﬁcantly reduced risk of fractures compared with population
controls (Table 4). Patients with normal testosterone levels had a
risk reduction of the same magnitude though the risk reduction
was short of statistical signiﬁcance here (p¼ 0.065).
Discussion
This study—the ﬁrst large population-based analyses of fracture
risk in patients with PCOS—shows that the risk of fractures is
reduced in women with PCOS. Interestingly, the risk reduction
tended to bemore pronounced in women diagnosedwith PCOS
at a younger age and the risk reduction was not conﬁned to
traditional BMD-dependent fracture sites. We found no indica-
tion that women with PCOS were less exposed to daily trauma,
judged on their hospital contacts for strains and sprains. An
embedded subcohort analyses showed that the risk reduction
for fractures was, if anything, more pronounced in normal-
weight women though conﬁdence intervals overlapped. The
presence of hyperandrogenemia did not materially modify
fracture risk, which was reduced by about a third both in PCOS
women with normal and raised androgens—albeit statistically
signiﬁcant only in the latter subgroup.
Adolescent girls with PCOS are characterized by hyper-
insulinemia and androgen excess,(14) which could be consistent
with the results of the present study. Here the risk reduction for
fractures tended to be more pronounced in women with a
younger age at diagnosis. With aging, beta-cell function declines
in women with PCOS and the risk of type 2 diabetes increases,
and testosterone levels have also been found to be lower in
women diagnosed after the age of 30 years.(15) Both these
reductions in bone anabolic hormones could theoretically
contribute to a less favorable fracture outcome in women with a
higher age at the time of PCOS diagnosis. Although insulin
resistance may protect against osteoporosis, the risk of fractures
is clearly increased once type 2 diabetes mellitus has developed,
and especially if this is long-standing and accompanied by
diabetes complications.(16–20) Young women with PCOS are
often characterized by anovulatory cycles.(21) As covered in
greater detail previously,(8) estradiol levels in late-cycle days are
often decreased in hirsute patients with oligomenorrhea despite
normal estradiol levels in the follicular phase, so it is likely that
regularly-cycling PCOS patients have normal or high (due to
aromatase activity in more abundant adipose tissue) estradiol
levels, whereas PCOS patients with amenorrhea or irregular
cycles as a group have lower serum estradiol. There is some
uncertainty about the net effect on the skeleton of having a
relatively high androgen level at the cost of reduced estrogens
in young women. After all, in postmenopausal women,
androgen treatment does increase BMD, albeit accompanied
by undesirable changes in lipoprotein levels.(22) Menopause
itself is accompanied by approximately a doubling of the
activation frequency even in cortical bone, thus creating a high
turnover state with an increased remodeling space and
increased cortical porosity,(23) accompanied by an increase in
Fig. 1. Flowchart of included participants.
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Table 2. Incidence Rate and Hazard Ratios Among PCOS Patients and Controls
Control PCOS Hazard Ratio and 95% CI Interaction terms
n
Per 1000 patient
years n
Per 1000 patient
years Unadjusted Adjusteda
Interaction with
age
Interaction with prior
fracture
Any fracture 6,148 13.6 1,596 10.3 0.76 (0.72–0.80)
p< 0.001
0.76 (0.71–0.80)
p< 0.001
p< 0.001 p¼ 0.73
Likely to be BMD dependent
Major osteoporotic
fractures
1,459 3.0 414 2.6 0.85 (0.76–0.95)
p¼ 0.003
0.82 (0.74–0.92)
p¼ 0.001
p¼ 0.31 p¼ 0.37
Forearm fractures 1063 2.2 293 1.8 0.83 (0.73–0.94)
p¼ 0.005
0.81 (0.71–0.93)
p¼ 0.002
p¼ 0.09 p¼ 0.78
Lower leg fractures 968 2.0 295 1.8 0.91 (0.80–1.04)
p¼ 0.15
0.89 (0.78–1.03)
p¼ 0.111
p¼ 0.16 p¼ 0.73
Fractures of femur or hip 141 0.3 29 0.2 0.61 (0.41–0.92)
p¼ 0.017
0.59 (0.38–0.90)
p¼ 0.013
p¼ 0.63 p¼ 0.54
Likely to be BMD independent
Fractures of hands 2,144 4.5 484 3.0 0.67 (0.61–0.74)
p< 0.001
0.68 (0.62–0.76)
p< 0.001
p< 0.001 p¼ 0.98
Fractures of head or face 691 1.4 130 0.8 0.56 (0.46–0.68)
p< 0.001
0.57 (0.47–0.70)
p< 0.001
p¼ 0.04 p¼ 0.54
PCOS¼polycystic ovary syndrome; CI¼ conﬁdence interval; BMD¼bone mineral density.
aAdjusted for Charlson index, prior fracture, prednisolone use, obesity, diabetes, dyslipidaemia, hyperthyroidism and hypothyroidism.
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fracture risk. Another scenario, in which the skeletal effects of
artiﬁcial androgen excess has been studied in younger women,
is in female-to-male transsexuals. Here, testosterone therapy
given in doses sufﬁcient to lower estradiol levels to the
postmenopausal range were able to induce BMD gains,
suggesting that androgen excess can increase BMD in adult
women in some settings.(24) However, ﬁndings in men have
revealed that estrogens appear to be critical in maintaining
skeletal health, at least in men, an area where androgen
sufﬁciency seems entirely unable to substitute for the lack of
estrogen bioactivity.(25) Certainly, extreme phenotypes such as
men with genetic defects in estrogen formation—due to
aromatase deﬁciency—or signaling—due to an inactivating
estrogen alpha receptor mutation—have displayed severe
osteoporosis as a pronounced feature.(26,27) Also, there may
be gender-speciﬁc differences in the nature of the skeletal
response to sex steroids, including the receptor subtypes
involved(28) and the direction of effect of some of the genetic
receptor variants.(29) Finally, the effect of male versus female sex
steroid hormones on the skeleton likely also depends on the
stage of skeletal development, so the effects of hyperandrogen-
ism in women of fertile age could depend on whether
hyperandrogenism debuted at a time when accretion of bone
mass was still taking place or at a later time in adult life.
In the present study, the fracture risk reduction was nominally
more pronounced in patients with BMI <25 kg/m2 than in
overweight patients. For osteoporotic fractures, the conven-
tional view among clinicians has long been that a high BMI was
protective against fracture, especially in postmenopausal
women where higher peripheral estrogen production and
higher weight bearing of bones would preserve strong bones
and prevent fractures. Recent research has shown this to be a
somewhat misguided view. Taken together, large cohort
studies(30) have consistently shown the association to be chieﬂy
driven by the strongly increased risk of fracture in those with low
BMI, whereas obesity confers little if any fracture risk reduction.
Although the risk of hip fracture is lower in obese postmeno-
pausal women, several studies have found an increased risk of
ankle and lower leg fractures as well as a possible increase in the
risk of vertebral fractures.(31) Women of normal body weight
are also less likely to be vitamin D–deﬁcient, but it is not clear if
the tendency for poorer vitamin D status in obesity is chieﬂy due
to lack of outdoor activity and sun exposure or whether the
amount of vitamin D deposited into adipose tissue also
contributes to this difference.(32) It is even possible that vitamin
D deﬁciency in itself affects adipogenesis (as reviewed in detail
elsewhere(33,34)) and the metabolic changes in PCOS show an
inverse relation with vitamin D status.(35) In premenopausal
women, abdominal adiposity is associated with decreased bone
formation rates, lower trabecular bone volume, and higher
cortical porosity.(36) In PCOS, central obesity is prevalent and is
present also in normal weight patients with PCOS.(37) Increased
secretion of interleukins and chemokines and decreased
adiponectin levels in PCOS may link central obesity, inﬂamma-
tory risk, and insulin resistance.(6,38) Our ﬁnding of reduced
fracture rate in PCOS suggests that the potential negative effects
on bone of visceral obesity, the associated low growth hormone
levels and increased cortisol levels,(39–41) did not materially
degrade bone strength in this age group.
A history of thyroid disorders—especially hypothyroidism—
was four times as prevalent among PCOS women compared
with population controls (Table 1). These ﬁndings were in
Fig. 2. Hazard ratios from the total Cox regression model with any
fracture as outcome and adjusted for all the baseline confounders.
Table 3. Adjusted Hazard Ratios for PCOS Patients and Controls Stratiﬁed by Age <30 years and 30 years
HR, adjusteda (95% CI)
Age< 30 (n¼ 38,618) Age 30 (n¼ 38,064)
Any fracture 0.66 (0.60–0.71) p< 0.001 0.86 (0.76–0.93) p< 0.001
Likely to be BMD dependent
Major osteoporotic fractures 0.75 (0.62–0.90) p¼ 0.002 0.87 (0.76–1.01) p¼ 0.07
Forearm fractures 0.69 (0.55–0.85) p¼ 0.001 0.90 (0.76–1.08) p¼ 0.26
Lower leg fractures 0.80 (0.64–1.00) p¼ 0.05 0.96 (0.81–1.15) p¼ 0.69
Fractures of femur or hip 0.65 (0.31–1.34) p¼ 0.24 0.60 (0.36–1.02) p¼ 0.06
Likely to be BMD independent
Fractures of hands 0.58 (0.50–0.67) p< 0.001 0.82 (0.71–0.95) p¼ 0.008
Fractures of head or face 0.46 (0.35–0.60) p< 0.001 0.79 (0.59–1.06) p¼ 0.12
PCOS¼polycystic ovary syndrome; HR¼hazard ratio; CI¼ conﬁdence interval; BMD¼bone mineral density.
aAdjusted for Charlson index, prior fracture, prednisolone use, obesity, diabetes, dyslipidaemia, hyper- and hypothyroidism.
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accordance with recent studies in which thyroid autoantibodies
and autoimmune thyroiditis were more prevalent in patients
with PCOS compared to controls.(42) Prolonged periods of
thyroid-stimulating hormone (TSH) suppression, whether from
overzealous thyroxine replacement therapy or from thyrotoxi-
cosis (in this age group generally Graves’ disease rather than
toxic nodular goiter) are known to substantially increase the risk
of fractures in adulthood.(43,44) However, though increased
relative to the background population, thyroid disorders were
still relatively infrequent and adjusting for a history of thyroid
disease did not affect our ﬁndings.
In this study, the womenwith PCOS hadmore contacts due to
strains and sprains that would typically be the consequence of
participation in sports. This indicates that it is not likely that the
women with PCOS were less physically active, at least not in the
time leading up to the diagnosis of PCOS. There are limited data
available regarding physical activity in women with PCOS
compared with controls.(45,46) The studies have opposite results
and included a small number of women.(45,46) One study from
Spain that included 22 women with PCOS and 59 controls
showed no overall signiﬁcant differences in the proportion of
women exercising regularly or in the number of hours of
exercise per week between overweight women with PCOS and
controls.(45) By contrast, another study from Greece, reporting
on 81 girls (35 with PCOS and 46 controls) showed that girls with
PCOS participated much less in physical activities than
controls.(46) Though a small study has reported increased
cortical BMD in the appendicular skeleton in PCOS women,
attributing our ﬁndings to this is premature.(47)
A major strength of this study is that it is population-based
and drew on awell-characterized local clinical cohort embedded
in national health databases, with a long follow-up period and a
complete prescription history since 1995. The National Patient
Register and the use of registries for diagnosis has high
validity.(48,49) The diagnosis of fractures has previously been
reported with an accuracy of 97%.(50)
Our study also has some potential limitations. In the age
group in question, many women have few or no hospital
contacts with the exception of childbirth. About one-quarter
of the control group participants had a hospital contact for
non-obstetric reasons in 1 calendar year (data not shown),
highlighting the importance of going over several years when
accounting for comorbid conditions or fracture outcomes. We
identiﬁed all PCOS patients from the Danish National register
based on all hospital contacts in Denmark, but some patients
with PCOS are treated by their general practitioner or by a
private gynecologist. Therefore, a group of women with PCOS
will not have been captured by national databases; we cannot
preclude the possibility that the women with PCOS not
attending the hospital differ from the women included in terms
of disease severity or socioeconomic status. This also leads to the
possibility that some of the “undiagnosed” PCOS women in the
study can be included in the control group and cause an
underestimation of the fracture risk reduction in PCOS women
by attenuation of the epidemiological signal.
Second, we lack direct information about physical activity
patterns and BMD information that would have allowed us to
further explore the potential mechanisms behind the reduction
in fracture risk in PCOS women.
Finally, there is a lack of information on BMI and
biochemistry data in the national cohort and in all controls,
but the differences between the embedded clinical subcohort
and the national PCOS cohort was very small in terms of age,
comorbidity, and prescription history.(10) Further, the risk
estimates were remarkably similar whether originating from
the national cohort or from the embedded subcohort with
extensive clinical information.
Conclusion
This study demonstrates that women with PCOS have a
substantially reduced risk of fractures, in particular of the
appendicular skeleton, which may not be fully explained by
obesity or reduced sports activity. The risk reduction was greater
in women with younger age at diagnosis, suggesting that the
skeletal effects of PCOS are more pronounced in women who
have not yet reached peak bone mass.
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